KLK2
| Kallikrein-1 | |
|---|---|
| Identifiers | |
| Symbol | ? |
| HGNC | 6346 |
| OMIM | 147910 |
| Other data | |
| EC number | 3.4.21.35 |
Kallikrein-1 (KLK1) is a serine protease enzyme encoded by the KLK1 gene in humans. It is a member of the kallikrein subfamily of serine proteases, which are involved in a variety of physiological processes. KLK1 is primarily known for its role in the kinin-kallikrein system, where it is responsible for the cleavage of kininogen to produce bradykinin, a potent vasodilator.
Structure[edit | edit source]
KLK1 is synthesized as a preproenzyme and undergoes several post-translational modifications to become an active enzyme. The mature enzyme consists of a single polypeptide chain with a molecular weight of approximately 30 kDa. The active site of KLK1 contains the classic serine protease triad: histidine, aspartate, and serine.
Function[edit | edit source]
KLK1 plays a crucial role in the regulation of blood pressure and electrolyte balance through the production of bradykinin. Bradykinin acts on B2 receptors to induce vasodilation, increase vascular permeability, and stimulate the release of other mediators such as prostaglandins and nitric oxide.
In addition to its role in the kinin-kallikrein system, KLK1 is involved in various other physiological processes, including inflammation, pain, and tissue remodeling. It is expressed in a wide range of tissues, including the kidney, pancreas, and salivary glands.
Clinical Significance[edit | edit source]
Alterations in KLK1 expression or activity have been implicated in several pathological conditions. For instance, reduced KLK1 activity is associated with hypertension, while increased activity has been observed in certain inflammatory diseases. KLK1 is also being investigated as a potential therapeutic target for conditions such as diabetic nephropathy and cardiovascular disease.
Research and Therapeutic Applications[edit | edit source]
Research into KLK1 has led to the development of kallikrein inhibitors and bradykinin receptor antagonists as potential therapeutic agents. These compounds are being explored for their ability to modulate the kinin-kallikrein system in diseases characterized by excessive inflammation or abnormal blood pressure regulation.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
